SARS-CoV-2 infection
infection, SARS-CoV-2 infection
INFECTION, SARS-COV-2 INFECTION
SARS-CoV-2 infection was defined in participants with negative SARS-CoV-2 status prebooster by either bAb levels against SARS-CoV-2 nucleocapsid protein (as measured by Roche ElecsysFor the analysis, documented infection was counted starting 14 days after the booster dose, which required a positive serology test result based on bAb specific to SARS-CoV-2 nucleocapsid at day 29 or later, or a positive RT–PCR result starting 14 days after the booster dose. The date of documented infection was the earlier of the date of a positive post baseline RT–PCR result or a positive serology test result based on bAb specific to SARS-CoV-2 nucleocapsid. The time to first SARS-CoV-2 infection was calculated as the date of the first documented infection minus the date of injection +1. Cases were counted starting 14 days after the injection (date of documented infection minus date of the injection ≥14). SARS-CoV-2 infection cases are summarized based on tests performed at least 14 days after the booster dose.